ConductScience.org, home

Trial · NCT04449029

Adverse events3,312

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherAbnormal clotting factorBlood and lymphatic system disordersGSK3228836 for 24 Weeks (WK) (on NA Therapy)0680
otherAbnormal clotting factorBlood and lymphatic system disordersGSK3228836 for 12+12 WK (on NA Therapy)0670
otherAbnormal clotting factorBlood and lymphatic system disordersGSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)0680
otherAbnormal clotting factorBlood and lymphatic system disordersPlacebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)0230
otherAbnormal clotting factorBlood and lymphatic system disordersGSK3228836 for 24 WK (Not on NA Therapy)0700
otherAbnormal clotting factorBlood and lymphatic system disordersGSK3228836 for 12+12 WK (Not on NA Therapy)0670
otherAbnormal clotting factorBlood and lymphatic system disordersGSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)1681
otherAbnormal clotting factorBlood and lymphatic system disordersPlacebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)0240
otherAnaemiaBlood and lymphatic system disordersGSK3228836 for 24 Weeks (WK) (on NA Therapy)0680
otherAnaemiaBlood and lymphatic system disordersGSK3228836 for 12+12 WK (on NA Therapy)3674
otherAnaemiaBlood and lymphatic system disordersGSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)1681
otherAnaemiaBlood and lymphatic system disordersPlacebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)1231
otherAnaemiaBlood and lymphatic system disordersGSK3228836 for 24 WK (Not on NA Therapy)2702
otherAnaemiaBlood and lymphatic system disordersGSK3228836 for 12+12 WK (Not on NA Therapy)0670
otherAnaemiaBlood and lymphatic system disordersGSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)1681
otherAnaemiaBlood and lymphatic system disordersPlacebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)1241
otherCoagulopathyBlood and lymphatic system disordersGSK3228836 for 24 Weeks (WK) (on NA Therapy)0680
otherCoagulopathyBlood and lymphatic system disordersGSK3228836 for 12+12 WK (on NA Therapy)0670
otherCoagulopathyBlood and lymphatic system disordersGSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)0680
otherCoagulopathyBlood and lymphatic system disordersPlacebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)0230

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04449029/events